CN113646426A - 一种包含肿瘤抗原识别受体的免疫细胞及其应用 - Google Patents

一种包含肿瘤抗原识别受体的免疫细胞及其应用 Download PDF

Info

Publication number
CN113646426A
CN113646426A CN202080025192.5A CN202080025192A CN113646426A CN 113646426 A CN113646426 A CN 113646426A CN 202080025192 A CN202080025192 A CN 202080025192A CN 113646426 A CN113646426 A CN 113646426A
Authority
CN
China
Prior art keywords
immune effector
effector cell
cell
cells
s1pr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080025192.5A
Other languages
English (en)
Inventor
廖雪梅
黄经纬
陈卓
谢曼曼
李安迪
刘阳
夏广新
刘彦君
柯樱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Pharmaceuticals Holding Co Ltd
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of CN113646426A publication Critical patent/CN113646426A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

一种修饰的免疫效应细胞及其用途、包含该免疫效应细胞的细胞群和药物组合物。该修饰的免疫效应细胞的S1PR1蛋白的表达和/或活性被上调。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN202080025192.5A 2019-04-04 2020-04-03 一种包含肿瘤抗原识别受体的免疫细胞及其应用 Pending CN113646426A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910271566 2019-04-04
CN2019102715660 2019-04-04
PCT/CN2020/083129 WO2020200303A1 (zh) 2019-04-04 2020-04-03 一种包含肿瘤抗原识别受体的免疫细胞及其应用

Publications (1)

Publication Number Publication Date
CN113646426A true CN113646426A (zh) 2021-11-12

Family

ID=72664676

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080025192.5A Pending CN113646426A (zh) 2019-04-04 2020-04-03 一种包含肿瘤抗原识别受体的免疫细胞及其应用

Country Status (6)

Country Link
US (1) US20220195397A1 (zh)
EP (1) EP3964568A4 (zh)
JP (1) JP2022529618A (zh)
KR (1) KR20210150446A (zh)
CN (1) CN113646426A (zh)
WO (1) WO2020200303A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112830974B (zh) * 2021-01-08 2022-07-26 深圳市珈钰生物科技有限公司 一种嵌合抗原受体、载体、人树突状细胞、细胞系、实体肿瘤治疗药物及制备方法和应用
KR102578480B1 (ko) * 2021-04-12 2023-09-14 메디젠 테라퓨틱스, 인코포레이티드 항원에 노출된 cd8 t 세포의 활성화 및 증식 방법 그리고 그에 의해 제조된 항암 활성이 강화된 cd8 t 세포 및 그의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745099A (zh) * 2003-02-22 2006-03-08 阿维德克斯有限公司 修饰的可溶性t细胞受体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201990959A1 (ru) 2012-04-11 2020-02-10 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US9629877B2 (en) * 2013-05-14 2017-04-25 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (CAR) T-cells
SG10201900455YA (en) 2014-07-24 2019-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
DE20196219T1 (de) * 2014-09-26 2021-10-28 Baylor College Of Medicine Glypican-3-Spezifische Chimäre Antigenrezeptoren für adoptive Immuntherapie
TWI702290B (zh) * 2015-04-07 2020-08-21 富禾生醫股份有限公司 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途
CN106520693B (zh) * 2016-10-20 2019-11-22 清华大学 记忆b细胞前体细胞及其用途
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
EP4060027A4 (en) * 2019-11-13 2023-12-27 Shanghai Pharmaceuticals Holding Co., Ltd. TMEM59 PROTEIN DIMER OR CHIMERIC EXPRESSION RECEPTOR TO IMPROVE T-CELL FUNCTION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745099A (zh) * 2003-02-22 2006-03-08 阿维德克斯有限公司 修饰的可溶性t细胞受体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDRE P.BENECHET ET AL.: "T cell-intrinsic S1PR1 regulates endogenous effector T-cell egress dynamics from lymph nodes during infection", 《PNAS》, pages 2183 *
RADHIKA GUDI ET AL.: "Siva-1 promotes K-48 polyubiquitination of TRAF2 and inhibits TCR-mediated activation of NF-kappaB", 《J ENVIRON PATHOL TOXICOL ONCOL》, pages 1 - 21 *
陆文斌等: "TCR/CAR修饰的T细胞在肿瘤免疫治疗中的研究进展和优化策略", 《免疫学杂志》, pages 163 - 173 *

Also Published As

Publication number Publication date
JP2022529618A (ja) 2022-06-23
KR20210150446A (ko) 2021-12-10
US20220195397A1 (en) 2022-06-23
EP3964568A1 (en) 2022-03-09
EP3964568A4 (en) 2023-01-11
WO2020200303A1 (zh) 2020-10-08

Similar Documents

Publication Publication Date Title
US11085021B2 (en) Compositions and methods for TCR reprogramming using fusion proteins
JP7109789B2 (ja) 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CN107995913B (zh) 使用融合蛋白对tcr重编程的组合物和方法
US10604740B2 (en) Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
US20210079057A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
CN109415409B (zh) Flag标记的cd19-car-t细胞
CN112142854B (zh) 免疫调节特异性嵌合抗原受体细胞及制备方法和应用
CN110964121B (zh) 一种分泌il-7、il-15因子的cd19-car-t细胞及其应用
KR20210118426A (ko) 양자 세포 요법을 위한 표적화된 공자극을 제공하는 수용체
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
JP2019531718A (ja) 非機能性のｔ細胞受容体（ｔｃｒ）を有するｔ細胞を生成するための試薬、当該試薬を含む組成物、及びそれらの使用
CN113896801B (zh) 靶向人Claudin18.2和NKG2DL的嵌合抗原受体细胞及其制备方法和应用
CN113416260B (zh) 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用
CN113039209A (zh) 用于使用融合蛋白进行tcr重编程的组合物和方法
CN115003700A (zh) 促实体瘤浸润的增强型cart细胞及其制备方法和细胞药物
CN113646426A (zh) 一种包含肿瘤抗原识别受体的免疫细胞及其应用
CN116745313A (zh) 通过靶向整合ζ缺陷型嵌合抗原受体转基因重编程免疫细胞
CN112204135A (zh) 一种表达cd3抗体受体复合物的免疫细胞及其用途
JP2023540022A (ja) チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにＣＤ４４ｖ６を認識するＣＡＲ発現細胞
JP2023540023A (ja) Ｃｅａを認識するキメラ抗原受容体（ｃａｒ）発現細胞
JP2015092865A (ja) ヒト化抗ｃｄ２０キメラ抗原レセプター
WO2024066026A1 (zh) 靶向IL13Rα2的经优化的嵌合抗原受体及其用途
JP7054181B2 (ja) キメラ抗原受容体
CN114644716A (zh) 一种抗bxmas1嵌合抗原受体及其修饰的免疫细胞及应用
CN116041518A (zh) 靶向b7-h3的抗体或抗体片段、以及其在嵌合抗原受体免疫细胞疗法领域的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061062

Country of ref document: HK